EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia

Charles Ebuka Okafor, Syed Afroz Keramat, Namal N Balasooriya, Echezona H Dioji

Value in Health · 2025

DOI: 10.1016/j.jval.2025.01.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Charles Ebuka Okafor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Services Research, Faculty of Health, Medicine & Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia. Elec…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: There is a progressive decline in the relative effectiveness of updated COVID-19 vaccines. Surveillance reports in Australia have also shown a wide variation in the disease severity and mortality across age groups. This study aimed to perform a cost-utility analysis of the monovalent XBB.1.5 vaccine relative to no updated booster vaccine between September 2023 and August 2024. METHODS: A cost-utility analysis was performed using a Markov model from the healthcare system perspective for 3 different age groups (18-64, 65-74, and ≥75 years). Costs and outcomes with the monovalent XBB.1.5 vaccine were compared with no updated booster dose for 1 year. Health outcomes were expressed as quality-adjusted life years (QALYs), whereas costs were presented in 2023 Australian dollars. Aggregate distributional cost-effectiveness analysis and sensitivity analyses were performed. The willingness-to-pay threshold was set at A$50 000/QALY. RESULTS: The updated vaccine was dominant for the 18 to 64 years group and cost-effective for the 65 to 74 years group (incremental cost-effectiveness ratio [ICER] = A$10 786/QALY) and ≥75 years group (ICER = A$36,531/QALY) relative to no updated booster vaccine. The major determinants of the ICER was the vaccine uptake rate. There was inequality in health benefits between the older First Nations versus nonindigenous Australians. The results were robust to simultaneous changes in the parameters' values. CONCLUSIONS: The monovalent XBB.1.5 vaccine is cost-effective and still relevant for all adult age groups in Australia. Based on current evidence, the study findings support the promotion of booster vaccination for Australian adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesHumansAdultAustraliaCost-Benefit AnalysisMiddle AgedAgedAdolescentYoung AdultQuality-Adjusted Life YearsMarkov ChainsMaleAge FactorsFemaleImmunization, Secondary

Stichwörter der Autor:innen

AustraliaCOVID-19 vaccinebooster vaccinecost-effectiveness analysis

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Centre for Health Services Research, Faculty of Health, Medicine & Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia. Electronic address: c.okafor@uq.edu.au.
  • Centre for Health Services Research, Faculty of Health, Medicine & Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.
  • Torrens University, School of Public Health, Fortitude Valley, Brisbane, QLD, Australia.

Zitieren

APA

Okafor, C. E., Keramat, S. A., Balasooriya, N. N., & Dioji, E. H. (2025). Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia. Value in Health. https://doi.org/10.1016/j.jval.2025.01.014

Vancouver

Okafor CE, Keramat SA, Balasooriya NN, Dioji EH. Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia. Value in Health. 2025. doi:10.1016/j.jval.2025.01.014

BibTeX
@article{Okafor2025,
  author = {Okafor, Charles Ebuka and Keramat, Syed Afroz and Balasooriya, Namal N and Dioji, Echezona H},
  title = {Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia},
  journal = {Value in Health},
  year = {2025},
  doi = {10.1016/j.jval.2025.01.014}
}
Kostenlos starten →